Another old drug to see huge price increase in the US

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

Another old drug to see huge price increase in the US

INICIO/Políticas y legislación | Posted 14/11/2014 0 Post your comment

Catalyst Pharmaceuticals (Catalyst) is preparing to increase the price of Firdapse (3,4-diaminopyridine) for the rare disorder Lambert-Eaton Myasthenic Syndrome (LEMS). This comes despite the fact that the drug’s active ingredient has been on the market in the US for more than 20 years.

LEMS, which causes debilitating muscle weakness, where the immune system attacks the nerves that control the muscles, is so rare, and the drug is so easily available, that it is currently being given away for free in the US by Jacobus Pharmaceuticals.

Catalyst, however, has reported positive results from a phase III study of Firdapse as a treatment for LEMS and intends to seek US Food and Drug Administration (FDA) approval in early 2015. The price hike from Catalyst, once approved, is expected to be in the region of US$80,000.

The whole situation comes as a result of FDA’s 2006 Unapproved Drugs Initiative, which rewards companies for testing treatments that have been on the market for years, but have never been subjected to rigorous trials. FDA’s aim was to get unapproved drugs off the market and to protect patients from potential harm. However, with no authority over pricing, the programme allows drug companies to suddenly increase the price of commonly available drugs.

Other drugs that have already seen a huge increase in price under this initiative include premature birth prevention Makena (hydroxyprogesterone), gout treatment Colcrys (Colchicine), and scorpion antivenom Anascorp (centruroides).

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: Catalyst